Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Further Publications

Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: an autopsy study over 13-years

Mod Pathol

Maccio U, Wicki A, Ruschitzka F, Beuschlein F, Wolleb S, Varga Z, Moch H

doi: 10.1016/j.modpat.2024.100683

Further Publications

The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

Eur J Cancer

Shatila M, Cruz CC, Lu L, Abdul-Baki K, Baerman E, Takigawa K, Rivera AU, Lee IJ, Ngo S, Sperling G, Aleem AS, Menon R, Sullivan A, Vemulapalli V, Natha C, Gupta T, Khan A, Mittal N, Coleman G, Salim H, Wali S, Varatharajalu K, Kim KC, Reddy SA, Grivas P, Thomas AS, Wang Y

doi: 10.1016/j.ejca.2025.115405

Lung, Respiratory and Thoracic Cancer

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Lung Cancer

Sugai M, Amino Y, Fujishima S, Nibuya K, Iso H, Ito M, Tsugitomi R, Ariyasu R, Uchibori K, Yanagitani N, Nishio M

doi: 10.1016/j.lungcan.2025.108555

Lung, Respiratory and Thoracic Cancer

Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis

Lung Cancer

Iglesias Martinez B, Insa A, Cervera Ygual G, Gascón F, Domínguez Moran JA, Martín-Martorell P

doi: 10.1016/j.lungcan.2025.108464

Lung, Respiratory and Thoracic Cancer

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53

Lung Cancer

Wu M, Zhou N, Guan M, Wang Y, Wang Y

doi: 10.1016/j.lungcan.2024.108068

Skin Cancer

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

Int J Cancer

Virazels M, Lusque A, Brayer S, Genais M, Dufau C, Milhès J, Filleron T, Pagès C, Sibaud V, Mortier L, Dereure O, Ayyoub M, Fabre A, Andrieu-Abadie N, Pancaldi V, Colacios C, Meyer N, Ségui B, Montfort A

doi: 10.1002/ijc.35416

Lung, Respiratory and Thoracic CancerCOVID-19

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor

Lung Cancer

Iso H, Ariyasu R, Fujishima S, Ito M, Nibuya K, Sugai M, Tsugitomi R, Amino Y, Uchibori K, Yanagitani N, Ninomiya H, Seike M, Nishio M

doi: 10.1016/j.lungcan.2025.108631

Further Publications

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

JAMA Oncol

Saleem N, Wang J, Rejuso A, Teixeira-Pinto A, Stephens JH, Wilson A, Kieu A, Gately RP, Boroumand F, Chung E, Bonevski B, Carlino MS, Carroll R, Lim WH, Craig JC, Murakami N, Wong G

doi: 10.1001/jamaoncol.2025.2374

Related content

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: an autopsy study over 13-years

The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis